Pfizer to buy VC-backed biotech firm Therachon
Pfizer has agreed to acquire Therachon, a biotech company focused on rare diseases, for $340 million upfront with an additional $470 million in contingent payments. Goldman Sachs is serving as financial adviser to Therachon on the deal with Cooley LLP and Homburger AG providing legal advice. And, Arnold & Porter and Lenz & Staehelin are serving as legal advisers to Pfizer. Therachon is backed by Novo Holdings, Cowen Healthcare Investments, Pfizer Ventures, Tekla Capital Management LLC, Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative.
9 May 2019•4 mins read
